Key clinical point: Abatacept doesn’t appear to exacerbate COPD in patients with rheumatoid arthritis.
Major finding: Risks for COPD exacerbation, flu, bronchitis, and pneumonia were not significantly elevated versus those with other biologic DMARDs.
Study details: The MarketScan database review comprised 4,634 patients.
Disclosures: Dr. Suissa disclosed relationships with AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, and Novartis.
Suissa S et al. Semin Arthritis Rheum. 2019 Mar 16. doi: 10.1016j.semarthrit.2019.03.007.